Acute myocardial infarction (AMI) is afflicting young individuals more frequently nowadays. The present study was planned to evaluate the clinical and angiographic profile in adults aged less than 30 years, presenting with first AMI as data from Central India is very scarce. This cross-sectional study included 41 patients of STEMI with a mean age of 27 ± 2.8 years. Risk factors were male gender (95.1%), dyslipidemia (51.2%), tobacco consumption (48.8%), obesity (34.1%), and smoking (29.3%). Anterior wall myocardial infarction (AWMI) was the most common presentation (82.9%) with obstructive CAD noted in 61% cases frequently due to LAD coronary artery involvement (46.4%).
Evidence does not currently support the use of topiramate to improve treatment retention for cocaine use disorder, although it may extend cocaine abstinence with a similar risk of adverse events compared with placebo.
Current migraine preventive therapies are often unsatisfactory because of their limited efficacy, adverse effects, and drug interactions. An open-label, non-controlled study of botulinum toxin type A (BTX-A) suggested some benefits for patients with migraine. To assess the efficacy and safety of BTX-A, a randomized, double-blind, vehicle-controlled, parallel group study was conducted in 32 patients with a history of 2 to 8 migraine attacks per month, with or without aura. The patients were randomized to receive single administrations of 50-U BTX-A or vehicle injected into multiple sites of pericranial muscles at the same visit. Patients kept daily diaries in which they recorded outcome measures like migraine frequency, migraine severity, and the occurrence of migraine-associated symptoms. Patients graded symptoms on a 4-point scale ranging from grades 0 to 3 before and up to 3-months after treatment. The assessments were made at 0, 1, and 3 months. The primary efficacy parameters included number of headaches resolved (grade 3/2 to grade 0) and alleviation of other accompanying symptoms of migraine. The supplementary end point included improvement in quality of life (QOL). About 75% of patients reported complete relief to mild headache (grade 0-1) by BTX-A and none by placebo group. Patient' QOL parameters like energy/vitality and feelings and concerns about the treatment had shown considerable improvement. However, normal day-to-day work functioning and social interactions deteriorated. No adverse effects were reported in any of the patients in either of the groups during the study. It is evident from the study that pericranial injection of 50-U BTX-A showed good efficacy and tolerability as a prophylactic agent. However, this therapy will be expensive to the patients, but it is far superior in providing relief to the patients compared with existing therapies.
In the present study, efficiency of Saccharomyces cerevisiae and vitamin E together in ameliorating ochratoxicosis in broiler chickens was investigated. Day-old broiler chicks (320) were divided into 8 treatment groups (T1- control (basal diet); T2- T1+ 150 ppb OTA; T3-T2 + 0.05% SC + 100 mg vitamin E-VE; T4- T2 + 0.075% SC + 100 mg VE; T5- T2 + 0.1% SC + 100 mg VE; T6- T2 + 0.05% SC + 200 mg VE; T7- T2 + 0.075% SC + 200 mg VE; T8- T2 + 0.1% SC + 200 mg VE per kg diet). Each diet was fed to 5 replicated groups of 8 birds from 0 to 42 days of age. During overall growth period (0–6 weeks), the body weight gain (BWG) of birds fed ochratoxin contaminated diet (T2) was lower than that of control group (T1). The BWG of group T5, T7 and T8 was higher than T2 but statistically similar to that of control. During overall growth period, the FI in control group was statistically similar to other treatment groups. The FI in groups T7 and T8 was higher than that of group received basal diet with toxin (T2). The overall FCR in control group (T1) was lower than that of T2. The FCR in groups T3, T4 and T6 was higher than the control, but lower than that of T2. The FCR in groups T5, T7 and T8 was lower than T2 and statistically similar to that of control (T1).The overall liveability percentage in control group (T1) was higher than that of ochratoxin fed group (T2). The liveability percentage in group T3 was lower than control and similar to that of T2. The liveability percentage in groups T4 to T8 was statistically similar to that of control. Ochratoxin contamination in diet caused significant reduction in body weight gain, feed consumption, feed efficiency and livability percentage. It was concluded that inclusion of S. cerevisiae at 0.1% level along with 100 mg vitamin E per kg diet or S. cerevisiae at 0.075% level along with 200 mg vitamin E/kg diet to the ochratoxin (150 ppb) contaminated feed ameliorated the adverse effects of ochratoxicosis on production performance of broiler chickens.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.